Al18F-NOTA-Octreotide outperforms 18F-FDG in identifying rare renal metastases from pancreatic neuroendocrine tumor.
Hell J Nucl Med
; 27(1): 68-70, 2024.
Article
in En
| MEDLINE
| ID: mdl-38629821
ABSTRACT
We presented a case involving a 56-year-old man who had been experiencing shoulder and back pain for over a year, with extensive bone metastases revealed by a bone scan. To identify the primary source of these issues, the patients underwent a fluorine-18-fluorodeoxyglucose (18F-FDG) positron emission tomography/computed tomography (PET/CT) scan, which indicated moderate uptake in the right renal soft mass and low uptake in multiple osteolytic lesions. Pathological examination and immunohistochemical staining of the renal mass supported the diagnosis of neuroendocrine tumors. Subsequently, a novel somatostatin receptor imaging agent, Al18F-NOTA-octreotide (18F-OC), was performed to further investigate the source of metastatic lesions and to stage the tumor. The 18F-OC scan revealed a high-uptake lesion in the pancreatic head, as well as additional lymph node and bone metastases lesions. Compared to 18F-FDG, the 18F-OC demonstrated superior imaging capabilities and a significantly higher tumor-to-background ratio in neuroendocrine neoplasms, which contributed to improving the staging and treatment management.
Full text:
1
Collection:
01-internacional
Database:
MEDLINE
Main subject:
Pancreatic Neoplasms
/
Neuroendocrine Tumors
/
Fluorodeoxyglucose F18
/
Positron Emission Tomography Computed Tomography
/
Kidney Neoplasms
Limits:
Humans
/
Male
/
Middle aged
Language:
En
Journal:
Hell J Nucl Med
Journal subject:
MEDICINA NUCLEAR
Year:
2024
Document type:
Article
Affiliation country:
China
Publication country:
GR
/
GRECIA
/
GREECE
/
GRÉCIA